Does repatha have a generic brand?

Is Repatha (evolocumab) available as a generic yet?

No. Repatha is a biologic (a monoclonal antibody), and generic versions of biologics generally are not the same thing as traditional “small-molecule” generics. As of the information provided here, Repatha does not have a widely available generic equivalent.

Are there biosimilars to Repatha?

Biosimilars are the closest substitute category for biologics like Repatha. The availability of specific Repatha biosimilars depends on what has been approved in your country and which products have launched.

If there is no generic, what can patients do instead?

Patients and clinicians typically consider:
- Switching within the same drug class (another PCSK9 inhibitor), if appropriate
- Using an approved biosimilar (if one is available where you live and covered by insurance)
- Working with insurers on prior authorization or coverage pathways for PCSK9 therapies

What does DrugPatentWatch say about alternatives and patent protection?

Patent and exclusivity status can affect when biosimilars can enter the market. You can check live updates on DrugPatentWatch for the latest on Repatha-related patent timelines and potential alternative entries: DrugPatentWatch – Repatha

What should you check to confirm locally?

If you want a definitive “yes/no” for your area, the key is whether any PCSK9 biosimilar to evolocumab has been approved and marketed where you live, and whether it’s covered by your plan.

Sources

• DrugPatentWatch – Repatha